Literature DB >> 7486941

Liposomal amphotericin B therapy of murine histoplasmosis.

J R Graybill1, R Bocanegra.   

Abstract

Liposomal amphotericin B (AmBisome) was compared with amphotericin B deoxycholate for the treatment of disseminated murine histoplasmosis. Liposomal amphotericin B was well tolerated and, milligram for milligram, was as potent as amphotericin B deoxycholate.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7486941      PMCID： PMC162848          DOI： 10.1128/AAC.39.8.1885

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

Review 2.  Amphotericin B: delivery systems.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 3.  New methods of delivery of amphotericin B.

Authors:  H J Schmitt
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

4.  Transfer of protective immunity in murine histoplasmosis by a CD4+ T-cell clone.

Authors:  R Allendoerfer; D M Magee; G S Deepe; J R Graybill
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

5.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Authors:  F Meunier; H G Prentice; O Ringdén
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

6.  Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

Authors:  J Wheat; R Hafner; M Wulfsohn; P Spencer; K Squires; W Powderly; B Wong; M Rinaldi; M Saag; R Hamill; R Murphy; P Connolly-Stringfield; N Briggs; S Owens
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

7.  Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole.

Authors:  P K Sharkey-Mathis; J Velez; R Fetchick; J R Graybill
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-07

8.  Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.

Authors:  R M Tucker; D W Denning; L H Hanson; M G Rinaldi; J R Graybill; P K Sharkey; D Pappagianis; D A Stevens
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

9.  Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  J A Gondal; R P Swartz; A Rahman
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

10.  Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B.

Authors:  E Anaissie; V Paetznick; R Proffitt; J Adler-Moore; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267
View more
  7 in total

1.  Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.

Authors:  F C Odds; F Van Gerven; A Espinel-Ingroff; M S Bartlett; M A Ghannoum; M V Lancaster; M A Pfaller; J H Rex; M G Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 2.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 4.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

5.  Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.

Authors:  Gloria M González; Rolando Tijerina; Laura K Najvar; Rosie Bocanegra; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 6.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

7.  Liposomal Amphotericin B as Monotherapy in Relapsed Coccidioidal Meningitis.

Authors:  Ethan R Stewart; Matthew L Eldridge; Ian McHardy; Stuart H Cohen; George R Thompson
Journal:  Mycopathologia       Date:  2018-01-16       Impact factor: 2.574
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.